A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
Folate Receptor-Alpha Positive

Interventions

DRUG: Mirvetuximab Soravtansine
DRUG: Lubricating Eye Drops
DRUG: Prednisolone acetate ophthalmic suspension 1% eye drops
DRUG: Brimonidine tartrate ophthalmic solution eye drops

Sponsor

AbbVie